Max Chat
Share chart Selecta Biosciences, Inc.
Extended chart
Simple chart
About Selecta Biosciences, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.Main settings
IPO date
2016-06-22
ISIN
US8162121045
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 8.33 | 1 |
| P/BV | -47.65 | 0 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -20.92 | 0 |
| ROE | 34.64 | 9 |
| ROIC | 0 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.1813 | 10 |
| Debt/Ratio | 0.0321 | 10 |
| Debt/Equity | -64.96 | 10 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 134.42 | 10 |
| Yield Ebitda, % | 36.04 | 5 |
| Yield EPS, % | 603.18 | 10 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 10.42 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 10.41 $ | 0 $ | 0 $ | +0.0961 % | 0 % | 0 % |
| Month | 9.16 $ | 10.42 $ | 10.42 $ | +13.76 % | 0 % | 0 % |
| Three month | 10.67 $ | 8.77 $ | 13 $ | -2.34 % | 0 % | 0 % |
| Half a year | 18.36 $ | 8.77 $ | 19.99 $ | -43.25 % | 0 % | 0 % |
| Year | 14.24 $ | 8.77 $ | 25.14 $ | -26.83 % | 0 % | 0 % |
| 3 years | 4.2 $ | 0.5353 $ | 36.58 $ | +148.1 % | 0 % | 0 % |
| 5 years | 4.76 $ | 0.5353 $ | 36.58 $ | +118.91 % | 0 % | 0 % |
| 10 years | 0.5353 $ | 0.5353 $ | 52.66 $ | +1 946.57 % | 0 % | 0 % |
| Year to date | 19.23 $ | 8.77 $ | 19.99 $ | -45.81 % | 0 % | 0 % |
Main owners
| Institutions | Volume | Share, % |
| Blackrock Inc. | 15 490 374 | 9.98 |
| Vanguard Group Inc | 14 382 654 | 9.27 |
| Artal Group S.A. | 9 136 635 | 5.89 |
| Madison Avenue Partners, LP | 8 016 038 | 5.16 |
| FMR, LLC | 5 136 792 | 3.31 |
| Geode Capital Management, LLC | 4 769 548 | 3.07 |
| Nantahala Capital Management, LLC | 4 400 000 | 2.83 |
| State Street Corporation | 4 066 528 | 2.62 |
| JP Morgan Chase & Company | 3 002 058 | 1.93 |
| Goldman Sachs Group Inc | 2 676 538 | 1.72 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Dr. Carsten Brunn Ph.D. | President, CEO & Director | 4.67M | 1971 (54 years) |
| Mr. Blaine T. Davis | Chief Financial Officer | 2.49M | 1974 (51 year) |
| Mr. Matthew Bartholomae J.D. | General Counsel & Secretary | N/A | |
| Dr. Metin Kurtoglu M.D., Ph.D. | Chief Technology Officer | 398.28k | 1979 (46 years) |
| Dr. Chris Jewell Ph.D. | Chief Scientific Officer | 296.85k | 1982 (43 years) |
| Dr. Milos Miljkovic M.D., Ph.D. | Chief Medical Officer | N/A | 1984 (41 year) |
| Dr. Emily English Ph.D. | SVP & Head of Manufacturing | N/A | 1980 (45 years) |
| Mr. Yi Zhang Ph.D. | Senior Director of Technology | N/A |
About company
Address: United States, Watertown. MA, 65 Grove Street - Open in google maps, Open in yandex maps
Website: https://selectabio.com
Website: https://selectabio.com
